Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$353 Mln
Revenue (TTM)
$67 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-3.3
Face value
--
Shares outstanding
29,019,344
CFO
$35.11 Mln
EBITDA
$-54.45 Mln
Net Profit
$-99.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
| -16.7 | -8.1 | -16.7 | 147.0 | -31.3 | -23.7 | -7.8 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
| 174.3 | -38.6 | -79.8 | -37.8 | 77.6 | -31.9 | -12.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Enanta Pharmaceuticals (ENTA)
|
13.1 | 353.5 | 67.0 | -71.5 | -95.5 | -69.5 | -- | 2.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment... of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Address: 4 Kingsbury Avenue, Watertown, MA, United States, 02472 Read more
President, CEO & Director
Dr. Jay R. Luly Ph.D.
President, CEO & Director
Dr. Jay R. Luly Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Enanta Pharmaceuticals Inc (ENTA) is $13.14 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Enanta Pharmaceuticals Inc (ENTA) has given a return of -31.25% in the last 3 years.
Since, TTM earnings of Enanta Pharmaceuticals Inc (ENTA) is negative, P/E ratio is not available.
The P/B ratio of Enanta Pharmaceuticals Inc (ENTA) is 2.79 times as on 31-Mar-2026, a 29 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-3.13
|
3.95
|
|
2024
|
-1.89
|
1.70
|
|
2023
|
-1.76
|
1.09
|
|
2022
|
-8.78
|
3.33
|
|
2021
|
-14.54
|
2.88
|
The 52-week high and low of Enanta Pharmaceuticals Inc (ENTA) are Rs 17.15 and Rs 4.09 as of 04-Apr-2026.
Enanta Pharmaceuticals Inc (ENTA) has a market capitalisation of $ 353 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Enanta Pharmaceuticals Inc (ENTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.17
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.